BREEZOMETER
20.2.2020 18:37:08 CET | Business Wire | Press release
BreezoMeter, leading provider of air quality data, has won sought after funding & endorsement from the EU’s Horizon 2020 Research & Innovation programme. The research will focus on understanding air quality health impact & improving forecast methods.
Horizon 2020 is the biggest EU Research & Innovation programme, with nearly €80 billion of funding over 7 years. It’s the financial instrument of the ‘Innovation Union’, designed to secure Europe’s future global competitiveness. The grant is awarded to those demonstrating world-class science and industrial leadership.
The prestigious grant was awarded for AQ-Watch (Air Quality: Worldwide Analysis & Forecasting of Atmospheric Composition for Health). The project received funding from the European Union’s Horizon 2020 research and innovation programme under EC grant agreement No 870301.
The project is led by the Max Planck Institute for Meteorology, Hamburg, Germany - and coordinated by Prof. Dr. Guy Brasseur and Dr. Gabriela Adler, BreezoMeter Chief Scientist with a PhD in Atmospheric Chemistry & Climatology.
By providing air quality information at a resolution and granularity of up to 5 meters, BreezoMeter brings unique expertise. BreezoMeter will also partner with several leading institutions around the world in 10 different countries.
Ran Korber, CEO at BreezoMeter said, “We’re excited to win Horizon 2020. This endorsement from the European Commission proves the strong science behind what we do and helps in our quest to improve access to actionable air quality information & improve the health of billions worldwide.”
Professor Guy Brasseur, project coordinator, said, “We are very pleased to cooperate with BreezoMeter in AQ-Watch. As the world leader for accurate air quality data, BreezoMeter’s expertise will enable AQ-Watch to reach unprecedented levels of services to potential customers anywhere in the world.”
Horizon 2020 received over 120,000 eligible applications . BreezoMeter’s selection is a significant validation of their technology, enabling them to work with leading institutions to advance analysis and forecasting of air quality.
BreezoMeter:
BreezoMeter is the leading provider of street-level and real-time air quality information, including air pollution, pollen and active fires data. Their free Android and iOS apps help individuals protect themselves from harmful air exposure. Their APIs enable businesses to increase sales & product engagement. BreezoMeter is already integrated by leading brands across healthcare, smart home, automotive, and cosmetic industries.
AQ-Watch:
AQ-Watch (Air Quality: Worldwide Analysis & Forecasting of Atmospheric Composition for Health) is a project funded by the European Commission (Grant Agreement 870301) under the Horizon 2020 Programme. AQ-Watch solutions aim at improving air quality management and forecast, and thus contribute to a better public health and optimized services from the energy sector. A toolbox made of seven innovative products and services will be developed using state-of-the-art atmospheric models and European Copernicus datasets, and will be tested in three regions of the world: in Chile, in Colorado (USA) and in Beijing-Tianjin-Hebei area (China). The AQ-Watch consortium includes 12 top level institutes, applied science organizations and business-oriented partners from 10 countries.
Website: www.aq-watch.eu
View source version on businesswire.com: https://www.businesswire.com/news/home/20200220005742/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release
The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio
Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release
Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom